Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials

Overview

Journal Thromb Haemost

Publisher Thieme

Specialties Cardiology & Vascular Diseases
Hematology

Date 2022 Aug 1

PMID 35909257

Authors

Lesley G Mitchell

Daniel Roshammar

Fenglei Huang

Manuela Albisetti

Leonardo R Brandao

Lisa Bomgaars

Elizabeth Chalmers

Jacqueline Halton

Matteo Luciani

David Joseph

Igor Tartakovsky

Savion Gropper

Martina Brueckmann

Affiliations

Soon will be listed here.

Abstract

Background: Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children.

Objectives: This population analysis characterized relationships between dabigatran total plasma concentrations and coagulation laboratory parameters (activated partial thromboplastin time [aPTT]; diluted thrombin time [dTT]; ecarin clotting time [ECT]).

Methods: Data from three phase 2a and one single-arm and one randomized, comparative phase 2b/3 pediatric studies (measurements: aPTT 2,925 [ = 358]; dTT 2,348 [ = 324]; ECT 2,929 [ = 357]) were compared with adult data (5,740 aPTT, 3,472 dTT, 3,817 ECT measurements; = 1,978). Population models were fitted using nonlinear mixed-effects modeling. Covariates (e.g., sex, age) were assessed on baseline and drug-effect parameters, using a stepwise covariate model-building procedure.

Results: Overall, relationships between dabigatran, aPTT, dTT, and ECT were similar in children and adults. For children aged <6 months, a higher proportion of baseline samples were outside or close to the upper aPTT and ECT adult ranges. No age-related differences were detected for dTT. With increasing dabigatran concentration, aPTT rose nonlinearly (half the maximum effect at 368 ng/mL dabigatran) while dTT and ECT increased linearly (0.37 and 0.73% change per ng/mL dabigatran, respectively). Mean baseline aPTT (45 vs. 36 seconds) and ECT (40 vs. 36 seconds) were slightly increased for those aged <6 months versus older children.

Conclusion: The similar relationships of laboratory parameters observed across pediatric age groups suggests that developmental changes in the hemostatic system may have little effect on response to dabigatran.

Citing Articles

The value of the old and the new.

Monagle P, Male C, Raffini L Blood Adv. 2023; 7(14):3683-3685.

PMID: 36939386 PMC: 10368678. DOI: 10.1182/bloodadvances.2023009723.

References

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

Chan A, Berry L, Monagle P, Andrew M . Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost. 2002; 87(4):606-13. View

Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J . Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015; 386(9994):680-90. DOI: 10.1016/S0140-6736(15)60732-2. View

Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V . Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2006; 94(6):1164-71. DOI: 10.1160/TH05-03-0215. View

Massicotte P, Leaker M, Marzinotto V, Adams M, Freedom R, Williams W . Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost. 1998; 80(4):570-4. View

Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin N, Yasui Y, Geisen C . In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010; 116(26):6101-5. DOI: 10.1182/blood-2010-05-283861. View

Raffini L, Huang Y, Witmer C, Feudtner C . Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009; 124(4):1001-8. DOI: 10.1542/peds.2009-0768. View

Halton J, Lehr T, Cronin L, Lobmeyer M, Haertter S, Belletrutti M . Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thromb Haemost. 2016; 116(3):461-71. DOI: 10.1160/TH15-04-0275. View

Monagle P, Chan A, Goldenberg N, Ichord R, Journeycake J, Nowak-Gottl U . Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e737S-e801S. PMC: 3278066. DOI: 10.1378/chest.11-2308. View

10.

Maas H, Gropper S, Huang F, Stangier J, Tartakovsky I, Brueckmann M . Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials. Thromb Haemost. 2018; 118(9):1625-1636. PMC: 6202931. DOI: 10.1055/s-0038-1668132. View

11.

Eriksson B, Dahl O, Huo M, Kurth A, Hantel S, Hermansson K . Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105(4):721-9. DOI: 10.1160/TH10-10-0679. View

12.

Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A . Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica. 2007; 92(4):554-7. DOI: 10.3324/haematol.10696. View

13.

Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen D . Development of the human coagulation system in the full-term infant. Blood. 1987; 70(1):165-72. View

14.

Schulman S, Kearon C, Kakkar A, Schellong S, Eriksson H, Baanstra D . Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368(8):709-18. DOI: 10.1056/NEJMoa1113697. View

15.

Dietrich K, Stang L, van Ryn J, Mitchell L . Assessing the anticoagulant effect of dabigatran in children: an in vitro study. Thromb Res. 2015; 135(4):630-5. DOI: 10.1016/j.thromres.2015.01.017. View

16.

Halton J, Brandao L, Luciani M, Bomgaars L, Chalmers E, Mitchell L . Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2020; 8(1):e22-e33. DOI: 10.1016/S2352-3026(20)30368-9. View

17.

Schulman S, Kakkar A, Goldhaber S, Schellong S, Eriksson H, Mismetti P . Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2013; 129(7):764-72. DOI: 10.1161/CIRCULATIONAHA.113.004450. View

18.

Weinstein J, Anderson S . The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010; 17(4):302-7. PMC: 2901622. DOI: 10.1053/j.ackd.2010.05.002. View

19.

Streif W, Andrew M, Marzinotto V, Massicotte P, Chan A, Julian J . Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999; 94(9):3007-14. View

20.

Halton J, Picard A, Harper R, Huang F, Brueckmann M, Gropper S . Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism. Thromb Haemost. 2017; 117(11):2168-2175. DOI: 10.1160/TH17-06-0429. View